The short version of thymosin beta-4 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-24 and is reviewed periodically as new material appears.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
== Discovery == Islets of Langerhans were first discussed by Paul Langerhans in his medical thesis in 1869. This same year, Édouard Laguesse named them after Langerhans. At first, there was a lot of controversy about what the Islets were made of and what they did. It appeared that all of the cells were the same within the Islet, but were histologically distinct from acini cells. Laguesse discovered that the cells within the Islets of Langerhans contained granules that distinguished them from acini cells. He also determined that these granules were products of the metabolism of the cells in which they were contained. Michael Lane was the one to discover that alpha cells were histologically different than beta cells in 1907. Before the function of alpha cells was discovered, the function of their metabolic product, glucagon, was discovered. The discovery of the function of glucagon coincides with the discovery of the function of insulin. In 1921, Banting and Best were testing pancreatic extracts in dogs that had had their pancreas removed. They discovered that "insulin-induced hypoglycemia was preceded by a transient, rather mild hyperglycemia..." Murlin is credited with the discovery of glucagon because in 1923 they suggested that the early hyperglycemic effect observed by Banting and Best was due to "a contaminant with glucogenic properties that they also proposed to call 'glucagon,' or the mobilizer of glucose". In 1948, Sutherland and de Duve established that alpha cells in the pancreas were the source of glucagon.
=== Riken === While the JINR–LLNL collaboration had been studying fusion reactions with 48Ca, a team of Japanese scientists at the Riken Nishina Center for Accelerator-Based Science in Wakō, Japan, led by Kōsuke Morita had been studying cold fusion reactions. Morita had previously studied the synthesis of superheavy elements at the JINR before starting his own team at Riken. In 2001, his team confirmed the GSI's discoveries of elements 108, 110, 111, and 112. They then made a new attempt on element 113, using the same 209Bi + 70Zn reaction that the GSI had attempted unsuccessfully in 1998. Despite the much lower yield expected than for the JINR's hot fusion technique with calcium-48, the Riken team chose to use cold fusion as the synthesised isotopes would alpha decay to known daughter nuclides and make the discovery much more certain, and would not require the use of radioactive targets. In particular, the isotope 278113 expected to be produced in this reaction would decay to the known 266Bh, which had been synthesised in 2000 by a team at the Lawrence Berkeley National Laboratory (LBNL) in Berkeley. The bombardment of 209Bi with 70Zn at Riken began in September 2003. The team detected a single atom of 278113 in July 2004 and published their results that September:
=== Paleobiology === Fungi are composed of soft tissues, making fossilization difficult and the discovery of fungal fossils rare. However, some exquisitely preserved specimens have been discovered in the middle Eocene Princeton Chert of British Columbia. These ectomycorrhizal fossils show clear evidence of a Hartig net, mantle and hyphae, demonstrating well-established EcM associations at least 50 million years ago. The fossil record shows that the more common arbuscular mycorrhizas formed long before other types of fungal-plant symbioses. Ectomycorrhizas may have evolved with the diversification of plants and the evolution of conifers and angiosperms. Arbuscular mycorrhizas may thus have been a driving force in the plant colonization of land, while ectomycorrhizas may have arisen either in response to further speciation as the Earth's climate became more seasonal and arid, or perhaps simply in response to nutritionally deficient habitats.
== Later career == Barron left Harvard University in 1995, when he joined Rice University as professor of Chemistry and Materials Science. He stepped down from his position at Gallia in 1997. In 1998, he was appointed as the Charles W. Duncan Jr.-Welch Foundation Chair in Chemistry at Rice University. Following his studies on ceramic nanoparticles and the discovery of their applications, he founded Oxane Materials in 2002. The company developed nanoproducts with applications in the field of energy. Building on his research with nanoparticles, Barron founded Natcore Technology in 2004 and joined the scientific advisory board of the company. The company manufactures nanoparticles and technology with applications in the solar sectors. From 2006 to 2008, he served as the Associate Dean of Industry Interactions and Technology Transfer at the Rice University. In 2019 he was appointed as the Prince of Wales Visiting Innovator with an appointment at the University of Wales. In 2013 he was appointed as the Sêr Cymru Chair of Low Carbon Energy and Environment, Swansea University. His research in the field of energy and environment resulted in his foundation of the Energy Safety Research Institute (ESRI), with the vision of "building the bridge to a sustainable, affordable and secure energy future." ESRI was housed in the first BREEAM Outstanding Building in Wales. Barron is the editor of Journal of Nanomaterials since 2013 and Scientific Reports since 2014. He is also part of the editorial boards of Main Group Chemistry and Materials Science in Semiconductor Processing.
Sources: en.wikipedia.org
As such, PBPK modeling can be used, inter alia, to evaluate the involvement of carrier-mediated transport, clearance saturation, enterohepatic recirculation of the parent compound, extra-hepatic/extra-gut elimination; higher in vivo solubility than predicted in vitro; drug-induced gastric emptying delays; gut loss and regional variation in gut absorption.
Counterfeit medicinal drugs include those with less or none of the stated active ingredients, with added, sometimes hazardous, adulterants, substituted ingredients, completely misrepresented, or sold with a false brand name. Otherwise, legitimate drugs that have passed their date of expiry are sometimes remarked with false dates. Low-quality counterfeit medication may cause any of several dangerous health consequences, including side effects or allergic reactions, in addition to their obvious lack of efficacy due to having less or none of their active ingredients. Since counterfeiting is difficult to detect, investigate, quantify, or stop, the quantity of counterfeit medication is difficult to determine. In 2003, the World Health Organization cited estimates that the annual earnings from substandard and/or counterfeit drugs were over US$32 billion. The considerable difference between the cost of manufacturing counterfeit medication and price counterfeiters charge is a lucrative incentive. Fake antibiotics with a low concentration of the active ingredients can do damage worldwide by stimulating the development of drug resistance in surviving bacteria. Courses of antibiotic treatment which are not completed can be dangerous or even life-threatening. If a low-potency counterfeit drug is involved, completion of a course of treatment cannot be fully effective. Counterfeit drugs have even been involved in clinical drug trials. Several technologies may prove helpful in combating the counterfeit drug problem.
== Introduction == Banting lived at the house in London for ten months, beginning in June, 1920. He attempted a private medical practice and when it was unsuccessful, he began working at the University of Western Ontario; his research for a lecture there was what inspired his 25 word idea that provided the key to discovering insulin, and prevented the certain death of those affected by diabetes. Banting returned to the University of Toronto to begin his research on insulin in the spring of 1921. Banting House is dedicated to the story behind the discovery of insulin, as well as Banting's life and career. Its galleries focus on everything from his time spent in London, to his contributions in both World Wars, to his efforts as an artist. Some notable artifacts include Banting's original art, desk, medicine cabinet, and bed frame, as well as his Military Cross, the KBE, and his official replica of the Nobel Prize. Banting House was designated a National Historic Site of Canada in 1997.
== Ethnic federalism == One of the most dramatic political changes overseen by the Transitional Government was the realignment of provincial boundaries on the basis of ethnolinguistic identity. This marked the beginning of Ethiopia's first federal administrative structure, made up of nine regional states (singular: ክልል kilil; plural: kililoch). Article Two of the Transitional Period Charter of Ethiopia formally proclaims the rights of ethnic groups within the country, which are officially referred to as nations or nationalities:"The right of nations, nationalities and peoples to self-determination is affirmed. to this end, each nation, nationality and people is guaranteed the right to: a./ Preserve its identity and have it respected, promote its culture and history and use and develop its language; b./ Administer its own affairs within its own defined territory and effectively participate in the central government on the basis of freedom, and fair and proper representation;
Most city residents who were exposed to the MIC gas were first made aware of the leak by exposure to the gas itself, or by opening their doors to investigate commotion, rather than having been instructed to shelter in place or to evacuate before the arrival of the gas in the first place.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.